Perrigo Company plc announced it has received final approval from the U.S. Food and Drug Administration and has launched an AB rated generic version of Epiduo® (adapalene and benzoyl peroxide) Gel, 0.1%/2.5%. Epiduo® Gel is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Market sales of Epiduo® Gel over the last 12 months were approximately $164 million, according to IMS Health.